OpenLobby.EU
Explore

Institut National de la Santé et de la Recherche Médicale

INSERM

Créé en 1964, l’Inserm est un établissement public à caractère scientifique et technologique, placé sous la double tutelle du ministère de la Santé et du ministère de la Recherche.

Lobbying Activity

Meeting with Stéphane Séjourné (Executive Vice-President) and

19 Dec 2025 · - Politiques publiques de santé au sein de l’UE - Innovation et financement de la recherche dans le domaine pharmaceutique et biomédical. - Partenariats industriels.

Response to EU cardiovascular health plan

12 Sept 2025

As part of Inserm (National Institute of Health and Medical Research), the only French public research organization entirely dedicated to human health, we strongly encourage that the following biomedical research areas need to be addressed to reduce the burden of cardiovascular diseases : Area 1 Innovative therapies for cardiovascular diseases: This research area aims at identifying clinically useful molecular and cellular mechanisms that can reverse the pathophysiology of chronic conditions and/or allow to repair/regenerate the damaged heart/vessels. It relies on the use of cell and non-cell-based approaches in combination with bioactive biomaterials/bio-engineered patches or grafts. Area 2 Understanding the interaction between CVD and other disorders: Cardiovascular diseases often co-exist with other diseases or multi-organ dysfunctions, including metabolic diseases such as diabetes and obesity. Given the already identified change of cardiovascular disease from an acute to a chronic disease, the interaction of chronic cardiovascular disease on other morbidities (and reverse) is increasingly important. Research in this field should generate new insights how these interactions may be translated into combined treatment of both disorders. Important is the potential interaction of cardiovascular disease and cancer or cardiovascular disease and diabetes/obesity. This is not only important at the level of drug related interaction for these diseases, but certainly also for the interaction in the pathophysiology of both diseases. Important also is the interaction between the cardiovascular compartment and other organ dysfunction (Brain, Liver, Kidney, Spleen etc..). The inter-organ dialogue during chronic diseases must be addressed taking into account the evolution of its footprint throughout life, from birth to death. Understanding the mechanisms of individual trajectories and adaptation throughout lifespan is a major challenge. This involves understanding individual adaptation to chronic diseases not only in its biological and physical dimensions, from the function of each organ to that of their homeostasis in the whole body, but also in its psychosocial and public health dimensions. The ultimate challenge is to identify the conditions for healthy adaptation and the reversibility of pathological trajectories. Area 3 Innovative tools for early diagnosis and personalized management strategies of cardiovascular diseases: In spite of considerable progresses in the recent years, the outcome of up to one third of patients affected by cardiovascular morbidities is not favorable. This can be due to a late diagnosis as well as to individual pathogenic conditions/factors. Precision treatment and personalized management strategies, including molecular profiling , functional imaging and AI-assisted algorithm developments should allow to detect early signals at the time when the pathology is clinically silent, monitor preventive measures and optimize the treatment at the individual scale.
Read full response

Meeting with Kasia Jurczak (Head of Unit Research and Innovation)

29 Aug 2025 · Presentation of ANRS-MIE, and exchange on areas of common interest such as the Partnership on pandemic preparedness and GloPID-R (the Global research collaboration for infectious disease preparedness).